Apyx Medical shares surge 11.17% intraday on 34% Q4 revenue growth driven by 17% Surgical Aesthetics increase from AYON device success.

Apyx Medical surged 11.17% intraday after reporting preliminary Q4 2025 revenue growth of 34%, driven by a 17% increase in its Surgical Aesthetics segment and a 51% revenue jump in that division due to the AYON device's successful launch. The company projected full-year 2025 revenue of $52.7–$52.9 million, a 10% year-over-year increase, despite a 21% decline in OEM revenue. The strong performance in Surgical Aesthetics, a key growth area, and overall revenue beat likely fueled investor optimism, aligning with the stock's upward movement.